Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
about
Signal transduction inhibitors in treatment of myelodysplastic syndromesRecent advances in antimultiple myeloma drug development.Current therapy of myelodysplastic syndromesClinical utility of lenalidomide in the treatment of myelodysplastic syndromesEzatiostat hydrochloride for the treatment of myelodysplastic syndromes.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Emerging biological therapies for the treatment of myelodysplastic syndromes.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.A tyrosine-reactive irreversible inhibitor for glutathione S-transferase Pi (GSTP1).Glutathione S -transferase π: a potential role in antitumor therapy
P2860
Q26829903-F49493F5-6BBC-4ACB-B592-3B410FD04AAFQ33416297-1C1B1C49-E447-42F3-9460-D67ED0CD46C5Q34013796-18021905-4275-4E04-9981-D6FA741635AAQ34783754-2F18CC27-C3F3-4080-B18D-56AF9753B817Q38365967-133C2A83-C8B8-4310-AFB2-DFF6A0291A08Q38678113-A339DB62-4D3E-4FF1-B242-8BEBFB50B377Q38758162-FCB0BF04-62B9-46A4-957D-C92E6E030161Q38834981-DC865E1D-6955-4305-9FC1-2D8BBD53D12BQ39413114-1BEB489E-9ABA-4F2A-9ECB-98E41E67FB00Q41859046-EEAF0F86-EEC0-4D28-9487-42C604B4EF4FQ58694500-40BD876D-FFA1-4E80-AA0D-F554D3E4753D
P2860
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase 1 dose-ranging study of ...... myelodysplastic syndrome (MDS)
@ast
Phase 1 dose-ranging study of ...... myelodysplastic syndrome (MDS)
@en
type
label
Phase 1 dose-ranging study of ...... myelodysplastic syndrome (MDS)
@ast
Phase 1 dose-ranging study of ...... myelodysplastic syndrome (MDS)
@en
prefLabel
Phase 1 dose-ranging study of ...... myelodysplastic syndrome (MDS)
@ast
Phase 1 dose-ranging study of ...... myelodysplastic syndrome (MDS)
@en
P2093
P2860
P356
P1476
Phase 1 dose-ranging study of ...... myelodysplastic syndrome (MDS)
@en
P2093
Deborah Mulford
Gail L Brown
Mikkael A Sekeres
Naomi Galili
Ralph Boccia
Roger M Lyons
Ruben A Mesa
Scott E Smith
P2860
P2888
P356
10.1186/1756-8722-5-18
P577
2012-04-30T00:00:00Z
P5875
P6179
1050452801